Sugi Predict

Sugi Predict / Compounds / SCHEMBL15099990

SCHEMBL15099990

SCHEMBL15099990

CC(=O)N1CC(F)C[C@H]1C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 8/20 0.39
▸ DPP8 Q6V1X1 1/20 0.39
▸ DPP9 Q86TI2 1/20 0.39
▸ ATM Q13315 1/20 0.38
▸ RIPK1 Q13546 1/20 0.37
▸ MAPT P10636 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CHRNB2 P17787 1/20 0.34
▸ CHRNA3 P32297 1/20 0.34
▸ CHRNA4 P43681 1/20 0.34
▸ CHRNB3 Q05901 1/20 0.34
▸ CHRNA6 Q15825 1/20 0.34
▸ MMP2 P08253 1/20 0.34
▸ ANPEP P15144 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ PIN1 Q13526 1/20 0.33
▸ PREP P48147 1/20 0.33
▸ GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13165476 1.00 DPP4 (0.39) DPP4DPP8DPP9ATMRIPK1
SCHEMBL20798666 0.83 RIPK1 (0.40) DPP4DPP8DPP9RIPK1MAPT
SCHEMBL19633882 0.81 MAPT (0.38) DPP4DPP8DPP9ATMMAPT
SCHEMBL3664998 0.81 DPP4 (0.41) DPP4DPP8DPP9RIPK1MAPT
SCHEMBL22005363 0.78 RIPK1 (0.32) DPP4DPP8DPP9RIPK1
SCHEMBL220386 0.78 — —
SCHEMBL14145678 0.78 — —
SCHEMBL17225490 0.78 DPP4 (0.46) DPP4DPP8DPP9RIPK1CHRNB2
SCHEMBL20221847 0.78 DPP4 (0.38) DPP4DPP8DPP9RIPK1
SCHEMBL20754267 0.77 ATM (0.41) ATMMAPTTSHRCHRNB2CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190022242-A1 NOVEL ANTI-MMP16 ANTIBODIES AND METHODS OF USE ABBVIE STEMCENTRX LLC (US) 2019-01-24 — — US disclosed
EP-3338793-A1 NOVEL SEZ6 MODULATORS AND METHODS OF USE AbbVie Stemcentrx LLC (US) 2018-06-27 — — EP disclosed
WO-2018107116-A1 METHODS OF REDUCING TOXICITY OF ANTIBODY DRUG CONJUGATES, AND COMPOSITIONS PRODUCED THEREBY ABBVIE STEMCENTRX LLC (US) 2018-06-14 — — WO disclosed
US-20180134717-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN LIMITED (GB) 2018-05-17 — — US disclosed
US-20180015178-A1 ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE ABBVIE STEMCENTRX LLC (US) 2018-01-18 — — US disclosed
WO-2017201442-A1 ANTI-DLL3 DRUG CONJUGATES FOR TREATING TUMORS AT RISK OF NEUROENDOCRINE TRANSITION ABBVIE STEMCENTRX LLC (US) 2017-11-23 — — WO disclosed
WO-2017184942-A1 NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE ABBVIE STEMCENTRX LLC (US) 2017-10-26 — — WO disclosed
US-20170307622-A1 KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES ABBVIE STEMCENTRX LLC (US) 2017-10-26 — — US disclosed
EP-3235820-A1 PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF Genentech, Inc. (US) 2017-10-25 — — EP disclosed
US-9775916-B1 Anti-DLL3 antibody drug conjugates for treating cancer ABBVIE STEMCENTRX LLC (US) 2017-10-03 — — US disclosed
US-20140363887-A1 DLL3 MODULATORS AND METHODS OF USE STEM CENTRX, INC. (US) 2014-12-11 — — US disclosed
US-20140363887-A1 DLL3 MODULATORS AND METHODS OF USE STEM CENTRX, INC. (US) 2014-12-11 — — US disclosed
US-20140363826-A1 DLL3 MODULATORS AND METHODS OF USE STEM CENTRX, INC. (US) 2014-12-11 — — US disclosed
US-20140364590-A1 DLL3 MODULATORS AND METHODS OF USE STEM CENTRX, INC. (US) 2014-12-11 — — US disclosed
US-20140364593-A1 DLL3 MODULATORS AND METHODS OF USE STEM CENTRX, INC. (US) 2014-12-11 — — US disclosed
US-20140363455-A1 DLL3 MODULATORS AND METHODS OF USE STEM CENTRX, INC. (US) 2014-12-11 — — US disclosed
WO-2014174111-A1 AXL ANTIBODY-DRUG CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2014-10-30 — — WO disclosed
EP-2662095-A1 Pyrrolobenzodiazepines and conjugates thereof Spirogen Sàrl (CH) 2013-11-13 — — EP disclosed
US-20130266595-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2013-10-10 — — US disclosed
EP-2528625-B1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN SARL (CH) 2013-07-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130266595-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF CD79B, BCL6B, DRD1 DPP4 4625/4885DPP8 4602/4885DPP9 4603/4885
US-20170307622-A1 KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES DLK1, LANCL1, DYNLL1 DPP4 1514/4885DPP8 475/4885DPP9 494/4885
US-20180015178-A1 ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE DLK1, DYNLL1, DYNLL2 DPP4 1788/4885DPP8 1001/4885DPP9 1354/4885
US-20180134717-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF HDAC10, PBDC1, PDCD10 DPP4 4002/4885DPP8 2930/4885DPP9 3352/4885
US-20140364593-A1 DLL3 MODULATORS AND METHODS OF USE DLK1, PDLIM5, PDCD1LG2 DPP4 2515/4885DPP8 1544/4885DPP9 2237/4885
US-20190022242-A1 NOVEL ANTI-MMP16 ANTIBODIES AND METHODS OF USE MMP16, MMP15, MMP17 DPP4 233/4885DPP8 204/4885DPP9 96/4885
US-20140364590-A1 DLL3 MODULATORS AND METHODS OF USE DLK1, PDLIM5, PDCD1LG2 DPP4 2515/4885DPP8 1544/4885DPP9 2237/4885
US-20140363887-A1 DLL3 MODULATORS AND METHODS OF USE DLK1, PDLIM5, PDCD1LG2 DPP4 2515/4885DPP8 1544/4885DPP9 2237/4885
US-20140363455-A1 DLL3 MODULATORS AND METHODS OF USE DLK1, PDLIM5, PDCD1LG2 DPP4 2515/4885DPP8 1544/4885DPP9 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.